longbridgelongbridge
  • Platform Features
    Features
    Investment ProductsPrivate Wealth ManagementTrading ToolsMarket Data ServicesAnalysis ToolsNews ServicesFor Developers
    Account Types
    For IndividualsFor Institutions
  • Café
longbridge
© 2026 Longbridge|Terms of ServicePrivacy Policy

AIMEI HEALTH TECHNOLOGY CO LTD COM USD0.0001 (SUB/RIGHTS 17/11/2028) | 10-Q: FY2025 Q3 Revenue: USD 0

Earnings Watch
Nov 18, 2025 at 09:09 PM
LongbridgeAII'm LongbridgeAI, I can summarize articles.

Revenue: As of FY2025 Q3, the actual value is USD 0.

EPS: As of FY2025 Q3, the actual value is USD 0.06.

EBIT: As of FY2025 Q3, the actual value is USD -612.32 K.

Segment Revenue

  • The company has not generated any operating revenue as of September 30, 2025, as it is a blank check company focused on identifying a target for a business combination.

Operational Metrics

  • Net Income: For the nine months ended September 30, 2025, net income was $961,651, compared to $2,108,102 for the same period in 2024. For the three months ended September 30, 2025, net income was $352,019, compared to $743,510 for the same period in 2024.
  • Formation and Operating Costs: For the nine months ended September 30, 2025, formation and operating costs were $585,170, compared to $662,765 for the same period in 2024. For the three months ended September 30, 2025, these costs were $130,152, compared to $200,019 for the same period in 2024.

Cash Flow

  • Operating Cash Flow: Net cash used in operating activities was - $521,868 for the nine months ended September 30, 2025, compared to - $477,158 for the same period in 2024.
  • Investing Cash Flow: Net cash provided by investing activities was $29,887,800 for the nine months ended September 30, 2025.
  • Financing Cash Flow: Net cash used in financing activities was - $29,391,161 for the nine months ended September 30, 2025.

Unique Metrics

  • Interest Income: Interest income earned on cash held in the Trust Account was $1,546,821 for the nine months ended September 30, 2025, compared to $2,770,867 for the same period in 2024.

Future Outlook and Strategy

  • Core Business Focus: The company is focused on completing a business combination with United Hydrogen Group Inc. The business combination is expected to close in early 2026, subject to shareholder approvals and regulatory clearances.
  • Non-Core Business: The company has extended the timeframe to complete a business combination multiple times, with the current deadline set for December 6, 2025.

Priority

  • The company emphasizes the completion of the business combination with United Hydrogen as a priority, with structured plans to meet the deadline and regulatory requirements.

Login to unlock1,640characters for free

Due to copyright restrictions, please log in to your Longbridge account to view this content.
Thank you for your understanding and support of licensed content.

AIMEI HEALTH TECHNOLOGY CO LTD COM USD0.0001 (SUB/RIGHTS 17/11/2028)

AIMEI HEALTH TECHNOLOGY CO LTD COM USD0.0001 (SUB/RIGHTS 17/11/2028)

AFJKR.US

Open

--

High

--

Low

--

Prev Close

--

P/ETTM

--

Market Cap

--

LongbridgeAI